EUVIMEDEUVIMED entdecken
Crossref

Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis

Jean-Michel Hannoun-Levi, Jocelyn Gal, Csaba Polgar, Vratislav Strnad, Kristina Loessl, Bulent Polat, Daniela Kauer-Domer, Renaud Schiappa, Crisitna Gutierrez

International Journal of Radiation Oncology*Biology*Physics · 2023-12 · 117 (5) · 1200-1210

DOI: 10.1016/j.ijrobp.2023.06.075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2023-12. Verfasst von Jean-Michel Hannoun-Levi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, France. Electronic address: jean-michel.hannoun-lev…. Hauptthemen laut MEDLINE: Breast Neoplasms, Brachytherapy. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: For second ipsilateral breast tumor event (2nd IBTE), second conservative treatment (2nd CT) combining lumpectomy plus accelerated partial breast reirradiation (APBrI) represents a curative option. The aim of this study was to analyze oncological prognostic factors for patients with a 2nd IBTE treated with 2nd CT. METHODS AND MATERIALS: An analysis of clinical practices was conducted across 7 academic hospitals/cancer centers in 6 European countries based on the GEC-ESTRO database. Patients presenting a 2nd IBTE occurring after conservative surgery (lumpectomy + axillary evaluation) and irradiation performed for the primary tumor underwent a 2nd CT with brachytherapy-based APBrI. The main outcome was 5-year cumulative incidence (CI) rate of second local relapse. All analyzed patients were classified according to risk groups for Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) accelerated partial breast irradiation (APBI) and molecular classification and time interval between first and second breast surgery (TIS1S2). Finally, we combined GEC-ESTRO APBI, molecular, and TIS1S2 risk groups, leading to the definition of a new score (named TAM: score based on the combination of time interval [T] between first and second surgery and APBI [A] and molecular [M] classifications) specifically designed for 2nd IBTE oncological outcome analysis. RESULTS: From July 1994 to January 2021, a total of 508 patients received a 2nd CT. At the time of 2nd IBTE, median age was 64.6 years (range, 56.2-72.6). With a median follow-up of 60.9 months (56.2-72.6), the 5-year second local relapse CI rate was 4% (95% confidence interval [95% CI], 2%-6%). The 5-year distant metastasis disease CI rate was 7% (95% CI, 4%-10%). Five-year disease-free and overall survival rates were 89% (95% CI, 86%-93%) and 91% (95% CI, 88%-94%), respectively. In multivariate analysis, TAM score was an independent prognostic factor for all the oncological items (P < .001) except disease-specific survival (P = .07) and overall survival (P = .09). The grade ≥3 late toxicity rate was 12.1%. CONCLUSIONS: This analysis of 2nd CT combining lumpectomy with APBrI for 2nd IBTE confirmed the excellent oncological results obtained after 2nd CT. Furthermore, the GEC-ESTRO TAM score appears to be an important prognostic factor, assisting patients and physicians in the decision-making process.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBrachytherapyHumansMiddle AgedFemalePrognosisConservative TreatmentMastectomy, SegmentalRecurrenceNeoplasm Recurrence, LocalTreatment Outcome

Autor:innen und Institutionen

  • Department of Radiation Oncology, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, France. Electronic address: jean-michel.hannoun-levi@nice.unicancer.fr.
  • Department of Epidemiology/Biostatistics, Antoine Lacassagne Cancer Centre, University Cote d'Azur, Nice, France.
  • Department of Oncology, Semmelweis University, Budapest, Hungary; Centre of Radiotherapy, National Institute of Oncology, Budapest, Hungary.
  • Department of Radiation Oncology, Erlangen University Hospital, Erlangen, Germany.
  • Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Department of Radiation Oncology, Wurzburg University, Wurzburg, Germany.

Zitieren

APA

Hannoun-Levi, J. M., Gal, J., Polgar, C., Strnad, V., Loessl, K., Polat, B., Kauer-Domer, D., Schiappa, R., & Gutierrez, C. (2023). Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis. International Journal of Radiation Oncology*Biology*Physics, 117(5), 1200-1210. https://doi.org/10.1016/j.ijrobp.2023.06.075

Vancouver

Hannoun-Levi JM, Gal J, Polgar C, Strnad V, Loessl K, Polat B, et al. Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis. International Journal of Radiation Oncology*Biology*Physics. 2023;117(5):1200-1210. doi:10.1016/j.ijrobp.2023.06.075

BibTeX
@article{HannounLevi2023,
  author = {Hannoun-Levi, Jean-Michel and Gal, Jocelyn and Polgar, Csaba and Strnad, Vratislav and Loessl, Kristina and Polat, Bulent and Kauer-Domer, Daniela and Schiappa, Renaud and Gutierrez, Crisitna},
  title = {Second Conservative Treatment for Local Recurrence Breast Cancer: A GEC-ESTRO Oncological Outcome and Prognostic Factor Analysis},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2023},
  volume = {117},
  number = {5},
  pages = {1200--1210},
  doi = {10.1016/j.ijrobp.2023.06.075}
}
Kostenlos starten →